Ab&B Bio-Tech soars on vaccine inclusion in China's national drug list

Ab&B Bio Tech JS

13/08/2025 06:27

** Ab&B Bio-Tech 2627.HK soars as much as 36.4% to HK$59.60, highest since debut on August 11

** Influenza vaccines developer says China's National Healthcare Security Administration announced inclusion of co's core product quadrivalent subunit influenza vaccine in preliminary National Commercial Health Insurance Innovative Drug List for this year

** Vaccine designed to offer broad protection against two influenza A viruses, two influenza B viruses

 (Reporting by Donny Kwok)

 ((donny.kwok@thomsonreuters.com))